Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study
Annovis Bio (NYSE: ANVS) partnered with NeuroRPM to deploy an FDA-cleared AI digital biomarker platform in its open-label Parkinson’s study (ANVS-25002), a 36-month, 25-site U.S. trial testing buntanetap.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Annovis Bio (NYSE: ANVS) partnered with NeuroRPM to deploy an FDA-cleared AI digital biomarker platform in its open-label Parkinson’s study (ANVS-25002), a 36-month, 25-site U.S. trial testing buntanetap. The study has enrolled 90 of an estimated 500 patients and combines wearable symptom monitoring with a skin-based alpha-synuclein assay reporting >90% sensitivity and specificity.
The initiative aims to capture real-world, continuous measures of bradykinesia, tremor and dyskinesia and link digital and biological biomarkers to better track treatment response and inform future trial design.
Positive
- FDA-cleared AI device for continuous PD symptom monitoring
- Skin alpha-synuclein biomarker with >90% sensitivity and specificity
- Study active across 25 U.S. sites, combining digital and biological data
Negative
- Open-label design may limit strength of causal efficacy claims
- Study duration of 36 months delays definitive long-term readouts
Details
News Market Reaction – ANVS
On Mar 19, the day this news came out, ANVS closed 8.10% above the previous close.
Data tracked by StockTitan Argus for the Mar 19 session.
Key Figures
- PD study duration
- 36 months
- Open-label ANVS-25002 Parkinson’s study treatment period
- Study sites
- 25 sites
- U.S. locations for ANVS-25002 Parkinson’s study enrollment
- Current enrollment
- 90 patients
- Patients enrolled in ANVS-25002 out of planned total
- Planned enrollment
- 500 patients
- Estimated total enrollment target for ANVS-25002
- Diagnostic sensitivity
- >90% sensitivity
- Alpha-synuclein skin assay diagnostic performance in Parkinson’s
- Diagnostic specificity
- >90% specificity
- Alpha-synuclein skin assay diagnostic performance in Parkinson’s
Historical Context
-
Fiscal 2025 results and progress of buntanetap trials with extended cash runway.
-
Announcement of two AD/PD 2026 presentations on PD data and Phase 3 AD trial.
-
DSMB cleared pivotal Phase 3 AD trial to continue with no safety concerns.
-
Plan for 36‑month open-label extension in PD targeting 500 patients and biomarkers.
-
Planned corporate update webinar on late-stage programs and near-term milestones.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
digital biomarker medical
bradykinesia medical
dyskinesia medical
phosphorylated alpha-synuclein medical
open-label medical
biomarker medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MALVERN, Pa., March 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced a partnership with NeuroRPM, a digital health technology company, to implement a new FDA-cleared artificial intelligence (AI) platform that collects movement data for symptom and disease management in its ongoing Parkinson’s study.
Annovis’ recently launched open-label study in PD patients (ANVS-25002) is currently enrolling participants across the 25 sites in the United States to test buntanetap for the duration of 36 months. As part of the initiative to advance management, monitoring, and data collection, the Company has entered into a partnership with NeuroRPM to introduce the first FDA-cleared AI-enabled medical device that allows to monitor the primary PD symptoms – bradykinesia, tremor, and dyskinesia. This information will serve as a digital biomarker, capturing real-time evidence of how disease symptoms change during the course of the study.
“We are excited to collaborate with NeuroRPM and believe that data-driven insights generated from its platform will complement our existing data collection and strengthen the evidence-based monitoring of disease progression throughout the trial,” commented Cheng Fang, Ph.D., Senior Vice President, Research and Development at Annovis. “The data generated in this open-label study, together with novel biomarkers, will produce a wealth of information and provide additional insights into our understanding of the disease trajectory and will help inform the design of future clinical trials.”
NeuroRPM digital biomarker benefits:
- AI-powered real-time detection of core Parkinson’s symptoms
- Improved access to patients via mobile and wearable application
- Medication tracking and schedule reminders
- Passive data collection that minimizes patient burden
- Enhanced understanding of treatment response in everyday life
“Understanding the real-world impact of a therapy like buntanetap is a sophisticated task, particularly when treatment effects may unfold over multiple timescales across a highly variable patient population,” commented Atila Omer, CEO of NeuroRPM. “Continuous wearable monitoring enables objective measurement in real-world settings, helping researchers develop a more granular understanding of treatment response and a stronger evidence base for how a therapy is performing in daily life.”
For the open-label study, in addition to the NeuroRPM’s digital biomarker assessing PD symptoms, Annovis is also implementing a highly accurate biomarker test for misfolded phosphorylated alpha-synuclein – a defining hallmark of Parkinson’s pathology. Measured via a minimally invasive skin procedure, the assay delivers objective pathological evidence of the disease with greater than
The ANVS-25002 study has currently enrolled 90 out of the estimated total 500 patients. Following the study, participants may have the option to continue using NeuroRPM technology for clinical monitoring by prescription. More information about the ANVS-25002 study can be found in Patient Portal or on ClinicalTrials.gov.
About NeuroRPM
Headquartered in Washington D.C., NeuroRPM is a digital health company focused on advancing the measurement and management of Parkinson’s disease (PD) through continuous, real-world monitoring and AI-enabled analysis of complex symptom and health data. The company’s proprietary FDA 510(k)-cleared technology platform uses wearable sensors and AI-powered advanced analytics to measure and quantify key motor symptoms of PD. By collecting motion data continuously during normal daily activities, NeuroRPM provides objective insight into symptom patterns, fluctuations, and treatment response over time. NeuroRPM’s technology is used in both clinical care and research to complement traditional assessments with a more continuous and granular understanding of how PD presents in everyday life.
About Annovis
Headquartered in Malvern, PA, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.
Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.
Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.